Metagenomi Therapeutics (MGX) Profit After Tax (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Profit After Tax for 4 consecutive years, with -$23.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 7.91% year-over-year to -$23.1 million; the TTM figure through Mar 2026 stood at -$85.9 million (down 10.19% YoY), while the FY2025 annual figure was -$87.9 million, down 12.57% from the prior year.
• Profit After Tax fell to -$23.1 million in Q1 2026 per MGX's latest filing, from -$22.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$10.7 million in Q2 2024 and bottomed at -$25.1 million in Q1 2024.
• Historically, Profit After Tax has averaged -$19.8 million across 4 years, with a median of -$19.9 million in 2025.
• Annual changes were most pronounced in 2024 — Profit After Tax rose 17.44% — and 2025, when it tumbled 85.38%.
• Metagenomi Therapeutics' Profit After Tax stood at -$19.2 million in 2023, then slipped by 21.81% to -$23.4 million in 2024, then increased by 3.72% to -$22.5 million in 2025, then decreased by 2.36% to -$23.1 million in 2026.
• Business Quant data shows MGX's Profit After Tax at -$23.1 million in Q1 2026, -$22.5 million in Q4 2025, and -$20.4 million in Q3 2025.